Biogen sends CEO to the exit, abandons Aduhelm sales team in $1B overhaul Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be FDA plays tooth fairy, awards clearance to VideaHealth's cavity-spotting AI OIG report reignites lawmakers' push for action on Medicare Advantage prior authorization Pfizer sticks to guns on $22B Paxlovid sales despite reports of lagging demand Kaufman Hall: Hospital outpatient volumes and revenue rebounds in March FDA proposes order forcing Philips to repair, replace or refund all recalled ventilators Another Pfizer gene therapy is free of FDA hold, but delay continues Wearable, AI-powered whole-breast ultrasound system cleared by the FDA Cerner's Q1 net earnings jump 20% as pending Oracle deal is expected to sail through EU antitrust review AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease Novartis’ Netflix moment? Big Pharma launches new on-demand video hub to boost digital engagement with doctors Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug Featured Story | By Angus Liu Biogen’s yearlong struggle with the controversial FDA approval and launch of Aduhelm has culminated in a deep overhaul reaching all the way to the CEO. read more |
| |
|---|
|
| | Power your data-science drug discovery Introducing the QIAGEN Biomedical Knowledge Base. The first expertly curated knowledge base that comes from high-quality manually curated content with granularity and causality that spans multiple domains. Learn more. |
Top Stories By Annalee Armstrong Sierra Oncology was ready to take momelotinib to the market, but it needed help. What started as an effort to find a strategic partner turned into a $1.9 billion buyout from GlaxoSmithKline, which didn’t just want an arm's-length deal. Chief Commercial Officer Luke Miels wanted it all. read more By Andrea Park The AI was built and trained using VideaHealth’s extensive database of dental X-rays, the Videa Factory, which the company says comprises the dental industry’s most diverse data set. read more By Robert King A major new report from an HHS watchdog on prior authorization denials in Medicare Advantage sparked an urgent effort to get Congress to act on the issue. read more By Fraiser Kansteiner Paxlovid’s first-quarter revenue haul may look slim, but plenty more sales are on the way in the next three months, Pfizer executives said on an earnings call Tuesday. The Big Pharma said its COVID-19 oral antiviral, Paxlovid, could soon get a boost from contracts in China and Europe. read more By Robert King Hospital and health system outpatient revenue and volumes rebounded in March after suffering major declines since the onset of the pandemic in 2020, Kaufman Hall reports. read more By Andrea Park Seemingly still dissatisfied with Philips’ handling of its ongoing respiratory device recall, the FDA is now considering taking further action to force the medtech to tighten up its response to the safety event. read more By Gabrielle Masson Another of Pfizer's gene therapies had been freed from an FDA clinical hold, but the study is not set to get underway immediately. read more By Andrea Park Scanning the entire breast volume with iSono's Atusa system takes only about one minute per side—a far cry from the 10 to 15 minutes it can take to complete manual probing. read more By Heather Landi Health IT giant Cerner brought in $206 million in net earnings for the first quarter of 2022, up 20% from $172 million during the same period a year ago. Software giant Oracle plans to buy the company in a $28 billion deal and said it would Cerner's business into more international markets. In the U.S. hospital market, Cerner continues to lose market share to competitor Epic. read more By Conor Hale The AI spots people whose hearts may be having trouble pumping blood out to the rest of the body. read more By Ben Adams Novartis is continuing its digital push under CEO Vas Narasimhan with a new Netflix-style approach to help connect with doctors and better learn what content resonates with them. read more By James Waldron With the future of its urinary tract infection drug in doubt, Spero Therapeutics has resorted to laying off three-quarters of its staff and dropping and pivoting to its mid-stage pipeline. read more |
